Last reviewed · How we verify

NCT04556929: EDGE

Enhanced Detection in Glioma Excision

Terminated NA Last updated 22 March 2024
What this trial tests

NA trial testing Intra-operative imaging of 5-ALA fluorescence using ultra-high sensitivity camera in Glioma in 4 participants. Terminated before completion.

Timeline
21 September 2020
Primary endpoint
3 November 2021
3 November 2021

Quick facts

Lead sponsorUniversity of Oxford
PhaseNA
StatusTerminated
Study typeINTERVENTIONAL
Allocationna
Designsingle group
Maskingnone
Primary purposediagnostic
Enrollment4
Start date21 September 2020
Primary completion3 November 2021
Estimated completion3 November 2021
Sites1 location across United Kingdom

Drugs / interventions tested

Conditions studied

Sponsor

University of Oxford

Who can join

18 and older, any sex, with Glioma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to determine whether use of an ultra-high sensitivity camera with enhanced imaging technology can be used during surgery to detect areas of brain tissue affected by diffuse glioma, a type of brain cancer.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

  1. Safe surgery for glioblastoma: Recent advances and modern challenges.
    Gerritsen JKW, Broekman MLD, De Vleeschouwer S, Schucht P, et al · · 2022 · cited 59× · PMID 36127890 · DOI 10.1093/nop/npac019

Verify or expand the search:

Other recruiting trials for Glioma

Currently open trials in the same condition.

Other University of Oxford trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04556929.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing